Press Release Details

Cerus Corporation to Webcast Third Quarter Financial Results Conference Call

October, 26 2004

CONCORD, CA, October 26, 2004 – In conjunction with Cerus Corporation's (Nasdaq: CERS) report of its third quarter financial results, a live webcast will be made of its conference call with Claes Glassell, president and CEO and William J. Dawson, vice president, finance and CFO.

What:Cerus Corporation third quarter financial results, with an update on progress and future outlook
When:Tuesday, November 9, 2004 at 4:30 p.m. ET
Contact:Lainie Corten / Cerus Corporation, 925-288-6319

The conference call is protected by copyright. It cannot be recorded or rebroadcast without Cerus' permission.

Cerus Corporation is developing novel technologies to provide safer and more effective therapeutic options to patients in areas with substantial unmet medical needs, particularly within the fields of cancer, infectious disease and blood safety. The Concord, California-based company is combining its proprietary vector technologies with public domain and proprietary antigens to develop new therapies for cancer and infectious disease. Cerus has two therapeutic cancer vaccine products in development using its Listeria vector technology, one in collaboration with MedImmune, Inc. and the other with Johns Hopkins University. Cerus is also collaborating with subsidiaries of Baxter International Inc. on the INTERCEPT Blood System, which is designed to enhance the safety of donated blood components by inactivating viruses, bacteria and other pathogens. The INTERCEPT Blood System is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System for platelets is approved for use in the European Union and Canada.

Helinx is a trademark of Cerus Corporation
Baxter and INTERCEPT are trademarks of Baxter International Inc.

If you are unable to participate during the live webcast, the call will be temporarily archived at

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600